Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.62 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.56 |
| ▸ | NAMPT | P43490 | 1/20 | 0.53 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CCNC | P24863 | 1/20 | 0.48 |
| ▸ | CDK8 | P49336 | 1/20 | 0.48 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6067927 | 0.98 | ALOX15 (0.60) | ALOX15NOTUMNAMPTCHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL29642862 | 0.98 | ALOX15 (0.60) | ALOX15NOTUMNAMPTCHRNB2CHRNA4 | |
| Trifluoroacetic Acid SCHEMBL2413465 | 0.91 | ALOX15 (0.51) | ALOX15NOTUMNAMPTCHRNB2CHRNA4 | |
| SCHEMBL10669859 | 0.84 | CYP4F2 (0.51) | NOTUMCHRNB2CHRNA4 | |
| SCHEMBL30588953 | 0.84 | MAPT (0.52) | NOTUMNAMPTCHRNB2CHRNA4MAPT | |
| SCHEMBL13113159 | 0.84 | CHRNB2 (0.53) | NOTUMNAMPTCHRNB2CHRNA4MAPT | |
| SCHEMBL1814097 | 0.84 | MAPT (0.52) | NOTUMNAMPTCHRNB2CHRNA4MAPT | |
| SCHEMBL2394585 | 0.83 | PLOD2 (0.58) | NOTUMNAMPTLMNAMAPT | |
| SCHEMBL15517627 | 0.82 | KMO (0.55) | ALOX15NOTUMLMNACA12CA1 | |
| SCHEMBL15429528 | 0.82 | CHRNB2 (0.56) | CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3704094-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| WO-2025098432-A1 | mIDH1/NAMPT DUAL-TARGET INHIBITOR AND USE THEREOF | 中国药科大学 | 2025-05-15 | — | — | WO | disclosed |
| CN-117510484-B | MIDH1/NAMPT double-target inhibitor and application thereof | 中国药科大学 | 2024-11-22 | — | — | CN | disclosed |
| US-20240166652-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2024-05-23 | — | — | US | disclosed |
| CN-117510484-A | mIDH1/NAMPT double-target inhibitor and application thereof | 中国药科大学 | 2024-02-06 | — | — | CN | disclosed |
| CN-116589402-A | Compound serving as NAMPT-PDE delta double-target inhibitor and application thereof | 中国人民解放军海军军医大学 | 2023-08-15 | — | — | CN | disclosed |
| US-20230014907-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED | 2023-01-19 | — | — | US | disclosed |
| WO-2021252849-A1 | INHIBITORS OF APOL1 AND USE OF THE SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-12-16 | — | — | WO | disclosed |
| US-20210179556-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | ABBVIE INC. | 2021-06-17 | — | — | US | disclosed |
| US-20200361941-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2020-11-19 | — | — | US | disclosed |
| US-5691323-A | BENZIMIDAZOL-2-ONES | MERCK & CO., INC. (US) | 1997-11-25 | — | — | US | disclosed |
| US-5644028-A | Process for producing peptide derivatives and salts therefor | JAPAN ENERGY CORPORATION (JP) | 1997-07-01 | — | — | US | disclosed |
| US-5574044-A | BENZIMIDAZOL-2-ONE COMPOUNDS FOR TREATMENT OF MYOPIA | MERCK & CO., INC. (US) | 1996-11-12 | — | — | US | disclosed |
| WO-1996013262-A1 | MUSCARINE ANTAGONISTS | MERCK & CO., INC. (US) | 1996-05-09 | — | — | WO | disclosed |
| EP-0574135-A1 | Process for producing peptide derivatives and salts thereof | JAPAN ENERGY CORPORATION (JP) | 1993-12-15 | — | — | EP | disclosed |
| US-4937268-A | TREATMENT OF ASTHMA, CHRONIC BRONCHITIS | GLAXO GROUP LIMITED (GB) | 1990-06-26 | — | — | US | disclosed |
| EP-0286242-A2 | Ethanolamine derivates, processes for their preparation and pharmaceutical compositions containing them | GLAXO GROUP LIMITED (GB) | 1988-10-12 | — | — | EP | disclosed |
| US-4524071-A | HISTAMINE H2-ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 1985-06-18 | — | — | US | disclosed |
| US-4404020-A | Certain esters of 2-[(2,6-dichloro-3-pyridyl)oxy]propionic acid, compositions containing same and their herbicidal properties | CIBA-GEIGY CORPORATION (US) | 1983-09-13 | — | — | US | disclosed |
| EP-0074229-A1 | Triazole gastric anti-secretory agents | PFIZER INC. (US) | 1983-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361941-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | ALOX15 639/4885NOTUM 4143/4885NAMPT 2047/4885 |
| US-20230014907-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | APOL1, APOB, NPC1L1 | ALOX15 164/4885NOTUM 350/4885NAMPT 2118/4885 |
| US-20210179556-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | BTK, SYK, MYD88 | ALOX15 2301/4885NOTUM 1324/4885NAMPT 1121/4885 |
| US-20240166652-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | ALOX15 639/4885NOTUM 4143/4885NAMPT 2047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.